News Eisai's full lecanemab phase 3 trial results for Alzheimer's... Following the news of two lecanemab-related deaths reported on the eve of the C
Oncology Servier’s ASCO 2025 Data: Advancing IDH-Mutated Cancer Treat... At ASCO 2025, Servier’s Becky Martin discusses IDH-mutated cancers, including key insights on Tibsovo & Voranigo, and the implications for patients.
